fda to reconsider tirzepatide says shortage is over after taking a second look Eli Lilly joins FDA as

Have a history of pancreatitis as there is a slight increased risk of developing pancreatitis on this medication Have gastroparesis due to it slowing down gastric emptying which can worsen gastroparesis Have hypertriglyceridemia, or extremely high triglyceride levels As with other agents in this class, tirzepatide has a boxed warning regarding rodent thyroid C-cell tumor findings and the uncertain relevance to humans

Choose nutrient-dense snacks over volume

Choose Tirzepatide if: Your primary goal is significant total body weight loss You have elevated glucose readings, prediabetes, and/or metabolic syndrome You struggle with appetite control and food volume Youre willing to tolerate GI side effects during dose titrations You want a compound with robust general population clinical data Choose Tesamorelin if: Your primary goal is visceral fat reduction without systemic appetite suppression You carry excess abdominal fat despite having a somewhat reasonable total body weight You want to preserve and/or enhance lean mass while reducing VAT You want to avoid GLP-1-related GI side effects You understand youre using it off-label if you dont have HIV-associated lipodystrophy Do NOT choose either if: You have a history of pancreatitis (Tirzepatide) You have active cancer (Tesamorelin) Youre pregnant or breastfeeding (both) Youre looking for a shortcut instead of addressing foundational metabolic health (both) These peptides are tools with specific mechanisms suited to specific applications

How to get tirzepatide out of your system is a common question for patients discontinuing Mounjaro or Zepbound